Bicara Therapeutics (BCAX) Current Assets (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Current Assets data on file, last reported at $544.9 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 15.75% year-over-year to $544.9 million; the trailing twelve-month figure through Mar 2026 stood at $544.9 million (up 15.75% YoY), and the FY2025 full-year result was $422.1 million, down 16.01% from the prior year.
• Current Assets for Q1 2026 stood at $544.9 million, up from $422.1 million in the prior quarter.
• Across five years, Current Assets topped out at $544.9 million in Q1 2026 and bottomed at $231.1 million in Q4 2023.
• The 4-year median for Current Assets is $457.6 million (2025), against an average of $429.3 million.
• The widest annual swing landed in 2024, when Current Assets soared 117.48%; it then plunged 42.98% in 2025.
• A 4-year view of Current Assets shows it stood at $231.1 million in 2023, then jumped by 117.48% to $502.5 million in 2024, then decreased by 16.01% to $422.1 million in 2025, then climbed by 29.11% to $544.9 million in 2026.
• The last three Current Assets figures came in at $544.9 million (Q1 2026), $422.1 million (Q4 2025), and $297.4 million (Q3 2025), per Business Quant data.

Peer Comparison